Australian government announces quarter-billion investment in oncology therapies

16 July 2018
2019_biotech_test_vial_discovery_big

Greg Hunt, Australian MP for Flinders and Minister of Health, has announced the government's intention to invest A$250,000 ($186,000) to improve access to four I-O therapies.

The therapies to be listed are;

  • Opdivo (nivolumab), developed by Bristol-Myers Squibb (NYSE: BMY).
  • Imbruvica (ibrutinib), developed by Pharmacyclics and Janssen, subsidiaries of AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ), respectively.
  • Neulasta (pegfilgrastim), developed by Amgen (Nasdaq: AMGN).
  • Pegasys (peginterferon alfa-2a), developed by Genentech, a subsidiary of Roche (SIX: ROG).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology